Longitudinal Impact of Urinary Diversion on Health‐Related Quality of Life After Radical Cystectomy: A Multicenter Study in Japan
Shuhei Yamada(Obihiro Kosei General Hospital), the Japanese Urological Oncology Group, Yoichi M. Ito(Hokkaido University), Fumihiko Urabe(Jikei University School of Medicine), Hiroshi Kitamura(Tohoku University), Yoshiyuki Matsui(Tokyo National Hospital), Akira Yokomizo(Kyushu University), Katsuyoshi Hashine(Shikoku Cancer Center), Yohei Satake(Tohoku University), Ataru Sazawa(Obihiro Kosei General Hospital), Rikiya Taoka(Kagawa University), Shigetaka Suekane(Kurume University), Junji Yatsuda(Kumamoto University), Ken Morita(Kushiro City General Hospital), Hiroyuki Nishiyama(University of Tsukuba), Nobuo Shinohara(Hokkaido University Hospital), Atsuro Sawada(University of Miyazaki), Yasuhiro Hashimoto(RIKEN), Shunichi Fukuhara(Fukushima Medical University), Shuichi Tatarano(Kagoshima University), Takanori Mochizuki(University of Yamanashi), Takashi Kobayashi(Kyoto University), Atsunari Kawashima(Osaka City University), Takashi Matsumoto(Kyushu University), Kohei Hashimoto(Sapporo Medical University), Jun Miki(Jikei University Kashiwa hospital), Keita Kobayashi(Yamaguchi University), Miho Sato(Sapporo University), Takahiro Kojima(Aichi Cancer Center), Takahiro Osawa(Hokkaido University Hospital), Toru Harabayashi(National Hospital Organization Hokkaido Medical Center), Atsushi Takahashi(Hakodate National Hospital), Sayaka Shimizu(Kyoto University)
Cited by 1
Related Papers
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
|Nature|2021|603
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Extracellular vesicles as biomarkers and therapeutic targets for cancer
|American Journal of Physiology-Cell Physiology|2019|412
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2021|411
A Glycine-rich RNA-binding Protein Mediating Cold-inducible Suppression of Mammalian Cell Growth
|The Journal of Cell Biology|1997|388